University of California San Francisco

Publications

Publications

  1. ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
    2025 | ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
    ' href="https://researcherprofiles.org/profile/669673233">UCSF Research Profile
  2. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
    2025 | PubMed
  3. ASO Visual Abstract: Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
    2025 | ASO Visual Abstract: Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
    ' href="https://researcherprofiles.org/profile/669673232">UCSF Research Profile
  4. Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group.
    2025 | PubMed
  5. ASO Author Reflections: Equity in the Surgical Management of the Axilla.
    2025 | PubMed
  6. ASO Visual Abstract: Accuracy of Breast MRI for Surgical Planning After Neoadjuvant Therapy for Patients with Invasive Lobular Carcinoma.
    2025 | ASO Visual Abstract: Accuracy of Breast MRI for Surgical Planning After Neoadjuvant Therapy for Patients with Invasive Lobular Carcinoma.
    ' href="https://researcherprofiles.org/profile/664961506">UCSF Research Profile
  7. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
    2025 | PubMed
  8. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
    2025 | PubMed
  9. Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.
    2025 | PubMed
  10. ASO Author Reflections: Accuracy of MRI in Invasive Lobular Carcinoma after Neoadjuvant Therapy: Impact of Non-mass Enhancement.
    2025 | PubMed
  11. Accuracy of Breast MRI for Surgical Planning After Neoadjuvant Therapy for Patients with Invasive Lobular Carcinoma.
    2025 | PubMed
  12. Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database.
    2025 | PubMed
  13. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    2025 | PubMed
  14. ASO Author Reflections: Reassessing Positive Margins in Breast-Conserving Surgery: The Role of Histology and Oncoplastic Surgery.
    2025 | PubMed
  15. ASO Visual Abstract: A Multi-institutional Analysis of Contralateral Axillary Metastases-Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer.
    2025 | PubMed
  16. Breast cancer diagnosis, management, and outcomes in transgender, nonbinary, and gender-diverse individuals: A multicenter cohort.
    2025 | Breast cancer diagnosis, management, and outcomes in transgender, nonbinary, and gender-diverse individuals: A multicenter cohort.
    ' href="https://researcherprofiles.org/profile/621713572">UCSF Research Profile
  17. Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
    2025 | Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
    ' href="https://researcherprofiles.org/profile/621713573">UCSF Research Profile
  18. I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
    2025 | I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
    ' href="https://researcherprofiles.org/profile/621713577">UCSF Research Profile
  19. Patient experiences of diagnosis and treatment of invasive lobular carcinoma: A qualitative study from a prospective registry.
    2025 | Patient experiences of diagnosis and treatment of invasive lobular carcinoma: A qualitative study from a prospective registry.
    ' href="https://researcherprofiles.org/profile/621713571">UCSF Research Profile
  20. Reframing hormone-positive DCIS management: Effects of adjuvant therapies and surgical extent on any invasive recurrence.
    2025 | Reframing hormone-positive DCIS management: Effects of adjuvant therapies and surgical extent on any invasive recurrence.
    ' href="https://researcherprofiles.org/profile/621713575">UCSF Research Profile
  21. Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
    2025 | Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
    ' href="https://researcherprofiles.org/profile/621713576">UCSF Research Profile
  22. Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.
    2025 | Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.
    ' href="https://researcherprofiles.org/profile/621713574">UCSF Research Profile
  23. A Multi-Institutional Analysis of Contralateral Axillary Metastases: Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer.
    2025 | PubMed
  24. Positive Margin Rates After Breast-Conserving Surgery by Histologic Subtype: A Systematic Review and Meta-analysis Evaluating the Impact of Oncoplastic Surgery.
    2025 | PubMed
  25. Abstract 2367: Changes in breast hormone signaling and inflammation underlie radiologic features of cancer risk.
    2025 | Abstract 2367: Changes in breast hormone signaling and inflammation underlie radiologic features of cancer risk.
    ' href="https://researcherprofiles.org/profile/613784695">UCSF Research Profile
  26. 410 Fine Needle Aspiration Biopsy of Breast Specimens Effectively Harvests Cells for Patient-Derived Organoids Modeling Breast Ductal Carcinoma In Situ.
    2025 | 410 Fine Needle Aspiration Biopsy of Breast Specimens Effectively Harvests Cells for Patient-Derived Organoids Modeling Breast Ductal Carcinoma In Situ.
    ' href="https://researcherprofiles.org/profile/602844888">UCSF Research Profile
  27. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.
    2025 | PubMed
  28. Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial.
    2025 | PubMed
  29. Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
    2024 | PubMed
  30. Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast and elevated BMI: An institutional cohort study.
    2024 | PubMed
  31. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
    2024 | PubMed
  32. Reply to: "Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)".
    2024 | PubMed
  33. Variation in surgical treatment by body mass index in patients with invasive lobular carcinoma of the breast.
    2024 | PubMed
  34. Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
    2024 | Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
    ' href="https://researcherprofiles.org/profile/536117482">UCSF Research Profile
  35. Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer.
    2024 | PubMed
  36. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    2024 | PubMed
  37. ASO Author Reflections: Evolving Paradigms in Axillary Management for Breast Cancer: Insights from the ISPY-2 Neoadjuvant Chemotherapy Trial.
    2024 | PubMed
  38. ASO Author Reflections: Detecting Local Recurrence After Primary Treatment for Invasive Lobular Carcinoma of the Breast.
    2024 | PubMed
  39. International survey on invasive lobular breast cancer identifies priority research questions.
    2024 | PubMed
  40. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
    2024 | PubMed
  41. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.
    2024 | PubMed
  42. Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery.
    2024 | PubMed
  43. Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
    2024 | Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
    ' href="https://researcherprofiles.org/profile/517540625">UCSF Research Profile
  44. Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
    2024 | Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
    ' href="https://researcherprofiles.org/profile/517540713">UCSF Research Profile
  45. The neoadjuvant approach to treatment of breast cancer: Multidisciplinary management to improve outcomes.
    2024 | The neoadjuvant approach to treatment of breast cancer: Multidisciplinary management to improve outcomes.
    ' href="https://researcherprofiles.org/profile/513920689">UCSF Research Profile
  46. Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
    2024 | Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
    ' href="https://researcherprofiles.org/profile/517540598">UCSF Research Profile
  47. I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
    2024 | I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
    ' href="https://researcherprofiles.org/profile/528966536">UCSF Research Profile
  48. Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment.
    2024 | PubMed
  49. ASO Author Reflections: The Oncologic Safety of Immediate Oncoplastic Approaches in Invasive Lobular Carcinoma.
    2024 | PubMed
  50. Oncologic Safety of Immediate Oncoplastic Surgery Compared with Standard Breast-Conserving Surgery for Patients with Invasive Lobular Carcinoma.
    2024 | PubMed
  51. Abstract PO4-02-03: Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub study.
    2024 | Abstract PO4-02-03: Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub study.
    ' href="https://researcherprofiles.org/profile/517540543">UCSF Research Profile
  52. Abstract PO5-26-07: Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance.
    2024 | Abstract PO5-26-07: Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance.
    ' href="https://researcherprofiles.org/profile/530785123">UCSF Research Profile
  53. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
    2024 | PubMed
  54. Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy.
    2024 | Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy.
    ' href="https://researcherprofiles.org/profile/480325636">UCSF Research Profile
  55. Management of Concurrent Malignant Phyllodes Tumor and Invasive Breast Carcinoma.
    2024 | PubMed
  56. Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer risk.
    2024 | PubMed
  57. ASO Visual Abstract: Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
    2024 | PubMed
  58. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
    2023 | PubMed
  59. ASO Visual Abstract: Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    2023 | PubMed
  60. Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.
    2023 | PubMed
  61. Letter to the Editor of Annals of Surgical Oncology concerning "Is Choosing Wisely Wise for Lobular Carcinoma in Patients over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns".
    2023 | PubMed
  62. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    2023 | PubMed
  63. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study.
    2023 | 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study.
    ' href="https://researcherprofiles.org/profile/450783903">UCSF Research Profile
  64. Erratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression - CORRIGENDUM.
    2023 | PubMed
  65. Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
    2023 | PubMed
  66. ASO Author Reflections: Menopausal Status Does Not Predict Successful Breast Conservation Surgery After Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma.
    2023 | PubMed
  67. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    2023 | PubMed
  68. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
    2023 | PubMed
  69. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
    2023 | PubMed
  70. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database.
    2023 | PubMed
  71. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.
    2023 | PubMed
  72. ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast.
    2023 | PubMed
  73. Editorial: Contrast mammography-a promising tool for the pre-operative evaluation of lobular breast cancer.
    2023 | PubMed
  74. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
    2023 | PubMed
  75. Metabolic Positron Emission Tomography in Breast Cancer.
    2023 | PubMed
  76. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    2023 | PubMed
  77. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
    2023 | PubMed
  78. Time to Surgery in Breast Cancer-Is Faster Always Better?
    2023 | PubMed
  79. 407 Moving from observational studies to a clinical trial: the impact of obesity and surgical weight loss on breast imaging, tissue, and cancer screening experience: the B-BRITE study.
    2023 | 407 Moving from observational studies to a clinical trial: the impact of obesity and surgical weight loss on breast imaging, tissue, and cancer screening experience: the B-BRITE study.
    ' href="https://researcherprofiles.org/profile/420601116">UCSF Research Profile
  80. 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression.
    2023 | 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression.
    ' href="https://researcherprofiles.org/profile/441711077">UCSF Research Profile
  81. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | PubMed
  82. Abstract HER2-14: HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | Abstract HER2-14: HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    ' href="https://researcherprofiles.org/profile/420600738">UCSF Research Profile
  83. Abstract P2-03-16: Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | Abstract P2-03-16: Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    ' href="https://researcherprofiles.org/profile/420601003">UCSF Research Profile
  84. Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP).
    2023 | Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP).
    ' href="https://researcherprofiles.org/profile/420600739">UCSF Research Profile
  85. Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas.
    2023 | Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas.
    ' href="https://researcherprofiles.org/profile/530785156">UCSF Research Profile
  86. Abstract P6-08-09: Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survival.
    2023 | Abstract P6-08-09: Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survival.
    ' href="https://researcherprofiles.org/profile/420600914">UCSF Research Profile
  87. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
    2023 | PubMed
  88. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes.
    2023 | PubMed
  89. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    2022 | PubMed
  90. Implementation, evaluation, and modification of a near-peer learning group in graduate surgical education.
    2022 | PubMed
  91. ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study.
    2022 | PubMed
  92. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    2022 | PubMed
  93. Hereditary vs Sporadic Invasive Lobular Carcinoma and Impact of Locoregional Therapy on Disease-Free Survival.
    2022 | Hereditary vs Sporadic Invasive Lobular Carcinoma and Impact of Locoregional Therapy on Disease-Free Survival.
    ' href="https://researcherprofiles.org/profile/450783926">UCSF Research Profile
  94. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
    2022 | PubMed
  95. See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency.
    2022 | See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency.
    ' href="https://researcherprofiles.org/profile/344526329">UCSF Research Profile
  96. The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
    2022 | PubMed
  97. ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype.
    2022 | PubMed
  98. Abstract LB021: Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer progression.
    2022 | Abstract LB021: Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer progression.
    ' href="https://researcherprofiles.org/profile/344526302">UCSF Research Profile
  99. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
    2022 | Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
    ' href="https://researcherprofiles.org/profile/425026061">UCSF Research Profile
  100. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
    2022 | PubMed
  101. Emotional Regulation in Surgery: Fostering Well-Being, Performance, and Leadership.
    2022 | PubMed
  102. Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can
    2022 | Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can
    ' href="https://researcherprofiles.org/profile/344526855">UCSF Research Profile
  103. Abstract P2-02-02: Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer.
    2022 | Abstract P2-02-02: Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer.
    ' href="https://researcherprofiles.org/profile/425025799">UCSF Research Profile
  104. Abstract P3-02-01: Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma.
    2022 | Abstract P3-02-01: Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma.
    ' href="https://researcherprofiles.org/profile/344526321">UCSF Research Profile
  105. Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers.
    2022 | Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers.
    ' href="https://researcherprofiles.org/profile/344526451">UCSF Research Profile
  106. Abstract P3-03-07: Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL.
    2022 | Abstract P3-03-07: Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL.
    ' href="https://researcherprofiles.org/profile/425026038">UCSF Research Profile
  107. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
    2021 | PubMed
  108. O13 BIOLOGIC VERSUS SYNTHETIC MESH IN VENTRAL HERNIA REPAIR: PARTICIPANT-LEVEL ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS AT ONE YEAR.
    2021 | O13 BIOLOGIC VERSUS SYNTHETIC MESH IN VENTRAL HERNIA REPAIR: PARTICIPANT-LEVEL ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS AT ONE YEAR.
    ' href="https://researcherprofiles.org/profile/249191066">UCSF Research Profile
  109. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
    2021 | PubMed
  110. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
    2021 | PubMed
  111. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
    2021 | PubMed
  112. Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
    2021 | PubMed
  113. Correction to: Applications of 3D printing in breast cancer management.
    2021 | PubMed
  114. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
    2021 | PubMed
  115. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.
    2021 | Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.
    ' href="https://researcherprofiles.org/profile/206692739">UCSF Research Profile
  116. Early onset, multiple, bilateral fibroadenomas of the breast: a case report.
    2021 | PubMed
  117. Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions.
    2021 | Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions.
    ' href="https://researcherprofiles.org/profile/192871192">UCSF Research Profile
  118. Preventing Recurrence in Clean and Contaminated Hernias Using Biologic Versus Synthetic Mesh in Ventral Hernia Repair: The PRICE Randomized Clinical Trial.
    2021 | PubMed
  119. Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.
    2021 | PubMed
  120. ASO Author Reflections: Changes in Primary Treatment Strategy for Invasive Lobular Carcinoma Highlight the Need for Better Predictors of Therapy Response.
    2021 | PubMed
  121. Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB).
    2021 | PubMed
  122. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
    2021 | PubMed
  123. Abstract PD5-01: Magnetic resonance imaging insights from an active surveillance cohort of women with DCIS.
    2021 | Abstract PD5-01: Magnetic resonance imaging insights from an active surveillance cohort of women with DCIS.
    ' href="https://researcherprofiles.org/profile/344527391">UCSF Research Profile
  124. Abstract PD6-08: DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy.
    2021 | Abstract PD6-08: DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy.
    ' href="https://researcherprofiles.org/profile/344527309">UCSF Research Profile
  125. Abstract PS1-03: Active surveillance for DCIS: Clinical outcomes at 5.6 years mean follow-up.
    2021 | Abstract PS1-03: Active surveillance for DCIS: Clinical outcomes at 5.6 years mean follow-up.
    ' href="https://researcherprofiles.org/profile/344527428">UCSF Research Profile
  126. Abstract PS17-05: Relationship between body mass index and tumor subtype by menopausal status: An analysis in women with lobular carcinoma of the breast.
    2021 | Abstract PS17-05: Relationship between body mass index and tumor subtype by menopausal status: An analysis in women with lobular carcinoma of the breast.
    ' href="https://researcherprofiles.org/profile/425026016">UCSF Research Profile
  127. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
    2021 | PubMed
  128. Applications of 3D printing in breast cancer management.
    2021 | PubMed
  129. A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines.
    2021 | PubMed
  130. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives.
    2021 | PubMed
  131. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.
    2020 | PubMed
  132. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
    2020 | PubMed
  133. 274 Poster Unintended bias in clinical trials: The prevalence of entry criteria that exclude patients with invasive lobular carcinoma from metastatic breast cancer trials.
    2020 | 274 Poster Unintended bias in clinical trials: The prevalence of entry criteria that exclude patients with invasive lobular carcinoma from metastatic breast cancer trials.
    ' href="https://researcherprofiles.org/profile/206692836">UCSF Research Profile
  134. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast.
    2020 | PubMed
  135. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.
    2020 | PubMed
  136. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
    2020 | PubMed
  137. 4314 The Impact of Axillary Surgery on Recurrence-Free Survival in Invasive Lobular Carcinoma (ILC) of the Breast.
    2020 | 4314 The Impact of Axillary Surgery on Recurrence-Free Survival in Invasive Lobular Carcinoma (ILC) of the Breast.
    ' href="https://researcherprofiles.org/profile/151837417">UCSF Research Profile
  138. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.
    2020 | Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.
    ' href="https://researcherprofiles.org/profile/117442410">UCSF Research Profile
  139. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    2020 | PubMed
  140. Abstract OT3-09-01: Use of Oncotype DX DCIS for disease management in a prospective DCIS registry.
    2020 | Abstract OT3-09-01: Use of Oncotype DX DCIS for disease management in a prospective DCIS registry.
    ' href="https://researcherprofiles.org/profile/565917321">UCSF Research Profile
  141. Abstract P3-08-16: The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL.
    2020 | Abstract P3-08-16: The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL.
    ' href="https://researcherprofiles.org/profile/530785130">UCSF Research Profile
  142. Abstract P4-13-01: Trends in primary management of invasive lobular carcinoma: An analysis of the National Cancer Database (NCDB).
    2020 | Abstract P4-13-01: Trends in primary management of invasive lobular carcinoma: An analysis of the National Cancer Database (NCDB).
    ' href="https://researcherprofiles.org/profile/425025972">UCSF Research Profile
  143. Abstract P5-08-05: Risk of subsequent events after initial diagnosis of ductal carcinoma in situ - A large multi-center registry study.
    2020 | Abstract P5-08-05: Risk of subsequent events after initial diagnosis of ductal carcinoma in situ - A large multi-center registry study.
    ' href="https://researcherprofiles.org/profile/425026060">UCSF Research Profile
  144. Abstract P6-16-06: Improved early stratification of invasive cancer risk using MRI in a ductal carcinoma in-situ short-term active surveillance cohort treated with neoadjuvant endocrine therapy.
    2020 | Abstract P6-16-06: Improved early stratification of invasive cancer risk using MRI in a ductal carcinoma in-situ short-term active surveillance cohort treated with neoadjuvant endocrine therapy.
    ' href="https://researcherprofiles.org/profile/344526857">UCSF Research Profile
  145. Abstract PD9-08: Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast.
    2020 | Abstract PD9-08: Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast.
    ' href="https://researcherprofiles.org/profile/425026037">UCSF Research Profile
  146. Pragmatic Trials and Approaches to Transforming Care.
    2020 | Pragmatic Trials and Approaches to Transforming Care.
    ' href="https://researcherprofiles.org/profile/117442167">UCSF Research Profile
  147. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
    2019 | PubMed
  148. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
    2019 | PubMed
  149. Editorial: Applying Margin Consensus Guidelines to Invasive Lobular Carcinoma of the Breast.
    2019 | PubMed
  150. Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment.
    2019 | PubMed
  151. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    2019 | PubMed
  152. Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
    2019 | PubMed
  153. Abstract 118: The Impact of Post-Operative Prophylactic Antibiotics in Immediate 2-Stage Prepectoral Breast Reconstruction.
    2019 | Abstract 118: The Impact of Post-Operative Prophylactic Antibiotics in Immediate 2-Stage Prepectoral Breast Reconstruction.
    ' href="https://researcherprofiles.org/profile/79295123">UCSF Research Profile
  154. Changes in mammographic density following bariatric surgery.
    2019 | PubMed
  155. Abstract P1-15-15: Accuracy of MRI after neoadjuvant therapy for invasive lobular carcinoma of the breast.
    2019 | Abstract P1-15-15: Accuracy of MRI after neoadjuvant therapy for invasive lobular carcinoma of the breast.
    ' href="https://researcherprofiles.org/profile/79295122">UCSF Research Profile
  156. Abstract P4-11-01: A simple intervention for long-term relief of chronic post mastectomy pain.
    2019 | Abstract P4-11-01: A simple intervention for long-term relief of chronic post mastectomy pain.
    ' href="https://researcherprofiles.org/profile/79291192">UCSF Research Profile
  157. Abstract P6-01-04: Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    2019 | Abstract P6-01-04: Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    ' href="https://researcherprofiles.org/profile/79289840">UCSF Research Profile
  158. Abstract PD7-06: Molecular subtypes of invasive lobular breast cancer in the I-SPY2 TRIAL.
    2019 | Abstract PD7-06: Molecular subtypes of invasive lobular breast cancer in the I-SPY2 TRIAL.
    ' href="https://researcherprofiles.org/profile/425025968">UCSF Research Profile
  159. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    2019 | PubMed
  160. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.
    2018 | PubMed
  161. ASO Author Reflections: Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    2018 | PubMed
  162. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    2018 | PubMed
  163. Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    2018 | PubMed
  164. 452 (PB-085) The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast.
    2018 | 452 (PB-085) The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast.
    ' href="https://researcherprofiles.org/profile/79296163">UCSF Research Profile
  165. Abstract P2-12-16: The use of oncoplastic surgical techniques to increase successful breast conservation in invasive lobular carcinoma of the breast.
    2018 | Abstract P2-12-16: The use of oncoplastic surgical techniques to increase successful breast conservation in invasive lobular carcinoma of the breast.
    ' href="https://researcherprofiles.org/profile/79296259">UCSF Research Profile
  166. Abstract P5-12-04: The impact of bariatric surgery on mammographic breast density.
    2018 | Abstract P5-12-04: The impact of bariatric surgery on mammographic breast density.
    ' href="https://researcherprofiles.org/profile/79296258">UCSF Research Profile
  167. Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention.
    2018 | Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention.
    ' href="https://researcherprofiles.org/profile/79296260">UCSF Research Profile
  168. Breast tumor location in BRCA mutation carriers and implications for prevention.
    2017 | Breast tumor location in BRCA mutation carriers and implications for prevention.
    ' href="https://researcherprofiles.org/profile/79295121">UCSF Research Profile
  169. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    2016 | PubMed
  170. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.
    2016 | PubMed
  171. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
    2015 | PubMed
  172. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
    2015 | PubMed
  173. Abstract PD1-5: Characterizing the Tumor Immune MicroEnvironment (TIME) in high-risk ductal carcinoma in situ.
    2015 | Abstract PD1-5: Characterizing the Tumor Immune MicroEnvironment (TIME) in high-risk ductal carcinoma in situ.
    ' href="https://researcherprofiles.org/profile/79291145">UCSF Research Profile
  174. Abstract 165: Suppressed immunity and macrophages characterize high risk high grade DCIS.
    2014 | Abstract 165: Suppressed immunity and macrophages characterize high risk high grade DCIS.
    ' href="https://researcherprofiles.org/profile/79291191">UCSF Research Profile
  175. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    2013 | PubMed
  176. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    2013 | PubMed
  177. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    2012 | PubMed
  178. Biology of breast cancer in Nigerian women: a pilot study.
    2012 | PubMed
  179. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    2012 | PubMed
  180. P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial.
    2011 | P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial.
    ' href="https://researcherprofiles.org/profile/79296257">UCSF Research Profile
  181. P4-09-19: PCNA+ Tumor Associated Macrophages Are Associated with M1 and M2 Gene Expression, and Confer Poor Prognosis in the Absence of Anti-Tumor Immune Environment.
    2011 | P4-09-19: PCNA+ Tumor Associated Macrophages Are Associated with M1 and M2 Gene Expression, and Confer Poor Prognosis in the Absence of Anti-Tumor Immune Environment.
    ' href="https://researcherprofiles.org/profile/79291190">UCSF Research Profile
  182. PD02-05: MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial.
    2011 | PD02-05: MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial.
    ' href="https://researcherprofiles.org/profile/79291189">UCSF Research Profile
  183. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    2011 | PubMed
  184. Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness.
    2011 | Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness.
    ' href="https://researcherprofiles.org/profile/79296256">UCSF Research Profile
  185. Benign Thoracic Disease in the Elderly.
    2011 | Benign Thoracic Disease in the Elderly.
    ' href="https://researcherprofiles.org/profile/79294957">UCSF Research Profile
  186. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    2011 | PubMed
  187. Abstract P2-09-11: Response of Invasive Lobular Cancers to Neoadjuvant Therapy.
    2010 | Abstract P2-09-11: Response of Invasive Lobular Cancers to Neoadjuvant Therapy.
    ' href="https://researcherprofiles.org/profile/79294956">UCSF Research Profile
  188. Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences.
    2010 | Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences.
    ' href="https://researcherprofiles.org/profile/79294955">UCSF Research Profile
  189. Long-term survival and renal transplantation in a monozygotic twin with cloacal dysgenesis sequence.
    2009 | PubMed
  190. Bacteriologic features of surgical site infections following breast surgery.
    2009 | PubMed
  191. Benign thoracic disease in the elderly.
    2009 | PubMed
  192. Variation in annual volume at a university hospital does not predict mortality for pancreatic resections.
    2009 | PubMed
  193. Image of the month--quiz case. Traumatic intramuscular cyst of the duodenum.
    2005 | PubMed
  194. Quality-of-life issues in psoriasis.
    2004 | PubMed